Abstract
The current coinfection and superinfection status in COVID-19 patients is a significant clinical concern. Bacteria represent a major threat group, increasing the risk of complications and mortality. This study investigates the primary respiratory pathogens prone to coexistence or superinfection in COVID-19 patients using metagenomic sequencing, providing valuable insights for the identification and treatment of SARS-CoV-2.
Introduction
While SARS-CoV-2 is the primary driver of the COVID-19 pandemic, it rarely acts in isolation. Clinicians have observed that secondary infections—where bacteria, fungi, or other viruses exploit a weakened immune system—significantly exacerbate disease severity. A major hurdle in clinical management is "diagnostic uncertainty," as distinguishing between a primary viral infection and a secondary bacterial one based solely on symptoms is notoriously difficult. This often leads to the empirical use of broad-spectrum antibiotics, which may not be effective and can contribute to antibiotic resistance. This study employs metagenomic sequencing to map the landscape of these co-existing pathogens, offering a blueprint for more precise clinical interventions.
Methods
The researchers utilized metagenomic Next-Generation Sequencing (mNGS) to analyze the respiratory microbiome. Unlike standard PCR tests that target specific sequences, mNGS sequences all genetic material (DNA and RNA) within a sample.
Sample Collection and Library Construction
A total of 56 nasopharyngeal swabs were collected from 42 confirmed COVID-19 patients in Chengdu, China. Metagenomic libraries were constructed following the extraction of total DNA and RNA from these samples.
Sequencing and Bioinformatics
Sequencing was performed on the Illumina HiSeq 4000 platform, producing a dataset of 308.6 GB. For taxonomic classification, the researchers employed the Krona methodology. Microbial communities were further analyzed using heatmaps and Pearson distance functions to cluster samples based on pathogen abundance.
Key Insights and Results
The study revealed several critical findings regarding the microbial environment of COVID-19 patients:
Bacterial Dominance
Although COVID-19 is primarily a viral disease, the abundance of bacteria in the nasopharynx was found to be significantly higher than that of viruses. Bacterial reads typically exceeded 1,000, whereas viral reads were generally below 500. Proteobacteria emerged as the dominant bacterial phylum, accounting for 47.6% of the microbial community.
Core Co-infectors and Viral Diversity
A consistent group of opportunistic pathogens, including Klebsiella pneumoniae, Streptococcus pneumoniae, and Haemophilus influenzae, was detected in nearly all samples. Notably, K. pneumoniae, S. pneumoniae, and S. aureus had a 100% detection rate. Among non-SARS-CoV-2 viruses, Human gammaherpesvirus 4 (EBV) was the most common co-infection (53%), suggesting that COVID-19 may trigger the reactivation of latent viruses. Other prevalent viruses included Avian leukosis virus (16%) and Pandoravirus species (~9.7%).
Microbiome Shifts and the Antibiotic Paradox
Symptomatic patients exhibited higher levels of specific bacterial groups, such as Cyanobacteria, Spirochaetes, and Tenericutes, compared to asymptomatic carriers. Interestingly, the core microflora did not differ significantly between patients who received antibiotics and those who did not, suggesting that empirical antibiotic treatments may not effectively target the specific pathogens present in the nasopharynx.
Discussion and Future Directions
This metagenomic analysis underscores the importance of bacterial management in COVID-19 patient care. However, the study has limitations, including a relatively small sample size from a single center and a focus on early-pandemic variants.
Future research will aim to identify pathogens specifically linked to geriatric complications and leverage mNGS data to develop "precision" antibiotic treatment protocols. The raw sequencing data is available in the NCBI Sequence Read Archive under accession number SRP273396 for further validation and study.
Summary updated